The Food and Drug Administration has approved a meningococcal ABCWY vaccine for use in individuals aged 10 to 25 years, according to a press release from manufacturer GSK. The vaccine targets 5 groups of the bacteria Neisseria meningitidis (A,B,C,W, and Y), which represent the most invasive meningococcal disease cases globally. The vaccine combines antigenic components of the meningococcal group B vaccine and meningococcal groups A, C, Y, and W-135 oligosaccharide diphtheria CRM197 conjugate vaccine. Trial data demonstrated that the newly approved vaccine has a safety profile consistent with existing meningococcal vaccines.
Fewer jabs: The idea is that broad serogroup coverage in a single vaccine offers protection while reducing the number of injections patients need, potentially improving vaccination rates. The Centers for Disease Control and Prevention recommends meningococcal vaccination for all adolescents as well as children and adults at increased risk. Full U.S. prescribing information is available on the GSK website.
Read More